在婴儿川崎病中使用Infliximab:超过8年的经验
C Ravali Pratima Goud1, Rhea Singh1, Anindita Nandi1
1Pediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India.
对于患有川崎病 (KD) 的婴儿,Infliximab (IFX) 是安全有效的,特别是用于治疗静脉注射免疫球蛋白 (IVIG) 耐药性和冠状动脉动脉瘤 (CAA). 这项研究表明,在接受IFX的婴儿中出现了积极的结果.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 川崎病 (KD) 是一种严重的儿科疾病.
- 有限的数据存在于infliximab (IFX) 在KD的婴儿使用.
研究的目的:
- 评估infliximab (IFX) 在被诊断为川崎病 (KD) 的婴儿中的有效性和安全性.
- 评估IFX在静脉注射免疫球蛋白 (IVIG) 耐药性和冠状动脉动脉瘤 (CAA) 回归的情况下的疗效.
主要方法:
- 对35名用IFX治疗的KD婴儿进行了回顾性分析.
- 根据IVIG耐药性和CAA变化后发烧的缓解来评估有效性.
- 监测了安全性和耐受性.
主要成果:
- 15名IVIG抗性的婴儿中有13名在24小时内发烧.
- 在接受治疗的婴儿中观察到冠状动脉动脉瘤 (CAA) 的显著回归或正常化.
- 在这个儿科队列中,IFX耐受性良好,并显示出良好的安全性.
结论:
- 因弗利西马布 (IFX) 是患有川崎病 (KD) 的婴儿的一种安全有效的治疗选择.
- IFX在治疗IVIG抗性KD和促进冠状动脉动脉瘤 (CAA) 衰退方面表现有前途.
更多相关视频
11:09An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
Published on: April 17, 2018
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
